Literature DB >> 9557719

Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection.

S J Polyak1, S McArdle, S L Liu, D G Sullivan, M Chung, W T Hofgärtner, R L Carithers, B J McMahon, J I Mullins, L Corey, D R Gretch.   

Abstract

To study hepatitis C virus (HCV) genetic mutation during interferon (IFN) therapy, the temporal changes in HCV quasispecies heterogeneity were compared before and after treatment for nine patients infected with HCV genotype 1, including four nonresponders, four responders who relapsed after therapy, and one responder who experienced a breakthrough of viremia during therapy. Nine untreated patients with an average time between specimens of 8.4 years served as controls. Sequences from the second envelope glycoprotein gene hypervariable region 1 (HVR1) and the putative IFN sensitivity-determining region (ISDR) of the nonstructural NS5A gene were analyzed by heteroduplex mobility assays and nucleotide sequencing. A strong positive correlation was found between the percent change in a heteroduplex mobility ratio (HMR) and percent change in nucleotide sequence (r = 0.941, P < 0.001). The rate of fixation of mutations in the HVR1 was significantly higher for IFN-treated patients than for controls (6.97 versus 1.31% change in HMR/year; P = 0.02). Similarly, a higher rate of fixation of mutations was observed in the ISDR for IFN-treated patients than for untreated controls, although the result was not significant (1.45 versus 0.15 amino acid changes/year; P = 0.12). On an individual patient basis, IFN therapy was associated with measurable HVR1 and ISDR mutation in nine of nine (100%) and two of nine (22.2%) patients, respectively. Evolution to IFN-resistant ISDR sequences was observed in only one of nine IFN-treated patients. These data suggest that IFN therapy frequently exerts pressure on the HCV envelope region, while pressure on the ISDR was evident in only a subset of patients. Thus, the selection pressures evoked on HCV genotype 1 quasispecies during IFN therapy appear to differ among different patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9557719      PMCID: PMC109659          DOI: 10.1128/JVI.72.5.4288-4296.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients.

Authors:  S Okada; Y Akahane; H Suzuki; H Okamoto; S Mishiro
Journal:  Hepatology       Date:  1992-09       Impact factor: 17.425

2.  Hypervariable regions in the putative glycoprotein of hepatitis C virus.

Authors:  M Hijikata; N Kato; Y Ootsuyama; M Nakagawa; S Ohkoshi; K Shimotohno
Journal:  Biochem Biophys Res Commun       Date:  1991-02-28       Impact factor: 3.575

3.  Divergent patterns of progression to AIDS after infection from the same source: human immunodeficiency virus type 1 evolution and antiviral responses.

Authors:  S L Liu; T Schacker; L Musey; D Shriner; M J McElrath; L Corey; J I Mullins
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

4.  Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa.

Authors:  G Squadrito; F Leone; M Sartori; B Nalpas; P Berthelot; G Raimondo; S Pol; C Bréchot
Journal:  Gastroenterology       Date:  1997-08       Impact factor: 22.682

5.  Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins.

Authors:  A J Weiner; M J Brauer; J Rosenblatt; K H Richman; J Tung; K Crawford; F Bonino; G Saracco; Q L Choo; M Houghton
Journal:  Virology       Date:  1991-02       Impact factor: 3.616

6.  Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus.

Authors:  K Yoshioka; S Kakumu; T Wakita; T Ishikawa; Y Itoh; M Takayanagi; Y Higashi; M Shibata; T Morishima
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

7.  Use of aminotransferase, hepatitis C antibody, and hepatitis C polymerase chain reaction RNA assays to establish the diagnosis of hepatitis C virus infection in a diagnostic virology laboratory.

Authors:  D Gretch; W Lee; L Corey
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

8.  Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections.

Authors:  A J Weiner; H M Geysen; C Christopherson; J E Hall; T J Mason; G Saracco; F Bonino; K Crawford; C D Marion; K A Crawford
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

9.  Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution.

Authors:  M Martell; J I Esteban; J Quer; J Genescà; A Weiner; R Esteban; J Guardia; J Gómez
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

10.  Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients.

Authors:  H Khorsi; S Castelain; A Wyseur; J Izopet; V Canva; A Rombout; D Capron; J P Capron; F Lunel; L Stuyver; G Duverlie
Journal:  J Hepatol       Date:  1997-07       Impact factor: 25.083

View more
  33 in total

1.  Current Views on Hepatitis C Virus Infection.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

2.  Significance of pretreatment analysis of hepatitis C virus genotype 1b hypervariable region 1 sequences to predict antiviral outcome.

Authors:  Catherine Gaudy; Alain Moreau; Pascal Veillon; Stephanie Temoin; Francoise Lunel; Alain Goudeau
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

3.  Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.

Authors:  Mitsuaki Sato; Shinya Maekawa; Nobutoshi Komatsu; Akihisa Tatsumi; Mika Miura; Masaru Muraoka; Yuichiro Suzuki; Fumitake Amemiya; Shinichi Takano; Mitsuharu Fukasawa; Yasuhiro Nakayama; Tatsuya Yamaguchi; Tomoyoshi Uetake; Taisuke Inoue; Tadashi Sato; Minoru Sakamoto; Atsuya Yamashita; Kohji Moriishi; Nobuyuki Enomoto
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

4.  Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.

Authors:  K Sandres; M Dubois; C Pasquier; J L Payen; L Alric; M Duffaut; J P Vinel; J P Pascal; J Puel; J Izopet
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  Wide range of quasispecies diversity during primary hepatitis C virus infection.

Authors:  Belinda L Herring; Rose Tsui; Lorraine Peddada; Michael Busch; Eric L Delwart
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy.

Authors:  S J Polyak; K S Khabar; M Rezeiq; D R Gretch
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system.

Authors:  Ana Maria Contreras; Yoichi Hiasa; Wenping He; Adam Terella; Emmett V Schmidt; Raymond T Chung
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

8.  Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C.

Authors:  Hui Li; Brian J McMahon; Susan McArdle; Dana Bruden; Daniel G Sullivan; Dave Shelton; Heike Deubner; David R Gretch
Journal:  Virology       Date:  2008-03-17       Impact factor: 3.616

9.  Genotyping hepatitis C virus by heteroduplex mobility analysis using temperature gradient capillary electrophoresis.

Authors:  Rebecca L Margraf; Maria Erali; Michael Liew; Carl T Wittwer
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

10.  Developing novel oncolytic adenoviruses through bioselection.

Authors:  Wen Yan; Galila Kitzes; Farid Dormishian; Lynda Hawkins; Adam Sampson-Johannes; Josh Watanabe; Jenny Holt; Vivian Lee; Thomas Dubensky; Ali Fattaey; Terry Hermiston; Allan Balmain; Yuqiao Shen
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.